•
Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone, marking it as the first innovative drug available in the region for migraine treatment. This milestone was announced on November 10, 2022, at a joint press conference held by the Hainan Boao Lecheng International Medical…
•
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss pharmaceutical giant Novartis (NYSE: NVS) and China-based Alibaba Health Information Technology Ltd (HKG: 0241). The collaboration aims to utilize digitization to enhance patient medication accessibility and provide one-stop health management services. Financial details of the…
•
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995, SHA: 688331) novel fusion protein telitacicept is set to receive breakthrough therapy designation (BTD) status for the treatment of myasthenia gravis (MG). This marks a significant step forward in addressing a rare and challenging autoimmune…
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands, and Suzhou, China, has announced a licensing agreement between its wholly owned subsidiary Nona Biosciences and US mRNA specialist ModernaTX, Inc. (NASDAQ: MRNA). The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for…
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand 1 (PD-L1) inhibitor sugemalimab, combined with chemotherapy as a first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) with PD-L1 expression ≥ 5%, has reached the primary endpoint of progression-free survival (PFS). This…
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has received marketing approval in Brazil for its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib). The in-house developed drug is now approved for the treatment of Waldenström’s macroglobulinemia (WM) and relapsed/refractory (r/r) marginal zone lymphoma (MZL)…
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a bridging Phase II clinical study assessing the safety and immunogenicity of its SCTV01E vaccine. The quadrivalent (Alpha + Beta + Delta + Omicron variants) S trimer protein…
•
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing the safety, efficacy, and pharmacokinetics of thrombopoietin in chronic primary immune thrombocytopenia (ITP) in children or adolescents has reached its pre-set primary endpoint. The results of the statistical analysis showed that the study group’s superiority…
•
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has announced the completion of a Series B financing round at USD 118 million. The round was led by Enavate Sciences, with participation from Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal…
•
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study for its SHP2 inhibitor BBP-398 in Chinese patients with advanced solid tumors. This marks a significant step forward in the development of BBP-398, which targets the SHP2 protein-tyrosine phosphatase. SHP2 links growth factor, cytokine, and…
•
Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed an initial public offering (IPO) with the Hong Kong Stock Exchange. The IPO is co-sponsored by Goldman Sachs and CICC. While the price has not been disclosed at this stage, the proceeds will be used…
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a multi-center, open-label, dose escalation and expansion Phase I study. The study will assess the safety, pharmacokinetics, and efficacy of its embryonic ectoderm development (EED) inhibitor APG-5918. The drug…
•
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau of Disease Control and Prevention have released the “National Health Informatization Planning” document for the 14th Five-Year Plan (FYP) period (2021-2025). This document outlines the achievements and challenges of the previous 13th FYP period and…
•
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings report, showing total revenues of USD 57.5 million for the three-month period, up 33% year-on-year (YOY) and a 19% increase compared to USD 43.1 million for the same period in 2021. Research and Development (R&D)…
•
The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline (GSK, NYSE: GSK) and the Chinese Association of STD and AIDS Prevention and Control (CASPC). The collaboration is part of an HIV Sustained Care Advocacy project initiated by the UK major and its joint venture…
•
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has accepted another market filing for its recombinant thrombopoietin for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. This marks a significant step forward in expanding the therapeutic indications for…
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at the 5th China International Import Expo (CIIE). The collaboration is focused on enhancing the management of cardiovascular and cerebrovascular diseases, particularly atrial fibrillation. The two companies will integrate their product and resource advantages to bolster…
•
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda Pharmaceutical Co., Ltd (TYO: 4502) and US firms Amazon Web Services (AWS) and Accenture. The collaboration also marks the initiation of “TakedaSpark+”, an innovation incubation platform launched by the Japan-based firm in 2021. Through this…